First Manhattan Co. maintained its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,900 shares of the specialty pharmaceutical company’s stock at the end of the second quarter. First Manhattan Co.’s holdings in Jazz Pharmaceuticals PLC were worth $295,000 at the end of the most recent quarter.
A number of other large investors have also bought and sold shares of the company. Monarch Partners Asset Management LLC acquired a new stake in Jazz Pharmaceuticals PLC during the first quarter valued at approximately $8,733,000. Canada Pension Plan Investment Board increased its stake in Jazz Pharmaceuticals PLC by 587.5% in the first quarter. Canada Pension Plan Investment Board now owns 82,651 shares of the specialty pharmaceutical company’s stock valued at $11,995,000 after buying an additional 70,629 shares in the last quarter. Wells Fargo & Company MN increased its stake in Jazz Pharmaceuticals PLC by 0.5% in the first quarter. Wells Fargo & Company MN now owns 503,759 shares of the specialty pharmaceutical company’s stock valued at $73,111,000 after buying an additional 2,529 shares in the last quarter. Sumitomo Mitsui Asset Management Company LTD increased its stake in Jazz Pharmaceuticals PLC by 16.8% in the first quarter. Sumitomo Mitsui Asset Management Company LTD now owns 4,910 shares of the specialty pharmaceutical company’s stock valued at $712,000 after buying an additional 707 shares in the last quarter. Finally, Profund Advisors LLC increased its stake in Jazz Pharmaceuticals PLC by 11.5% in the first quarter. Profund Advisors LLC now owns 2,877 shares of the specialty pharmaceutical company’s stock valued at $418,000 after buying an additional 296 shares in the last quarter. Institutional investors and hedge funds own 86.43% of the company’s stock.
Jazz Pharmaceuticals PLC (NASDAQ JAZZ) opened at 142.90 on Thursday. The stock has a market capitalization of $8.58 billion, a P/E ratio of 21.59 and a beta of 1.10. The firm’s 50-day moving average is $155.68 and its 200-day moving average is $146.56. Jazz Pharmaceuticals PLC has a 12-month low of $95.80 and a 12-month high of $163.75.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last released its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 EPS for the quarter, missing the consensus estimate of $1.85 by $0.13. Jazz Pharmaceuticals PLC had a return on equity of 23.80% and a net margin of 25.69%. The business had revenue of $394.39 million during the quarter, compared to the consensus estimate of $410.83 million. During the same quarter in the previous year, the business posted $2.67 earnings per share. Jazz Pharmaceuticals PLC’s quarterly revenue was up 3.5% compared to the same quarter last year. Analysts predict that Jazz Pharmaceuticals PLC will post $11.02 EPS for the current fiscal year.
Several equities research analysts recently commented on the stock. Zacks Investment Research downgraded shares of Jazz Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a research report on Tuesday, May 2nd. Royal Bank Of Canada set a $210.00 target price on shares of Jazz Pharmaceuticals PLC and gave the stock a “buy” rating in a research report on Tuesday, June 27th. Cantor Fitzgerald reiterated a “buy” rating and set a $197.00 target price on shares of Jazz Pharmaceuticals PLC in a research report on Tuesday, June 27th. Cowen and Company reiterated an “outperform” rating and set a $190.00 target price on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday, May 10th. Finally, Leerink Swann set a $179.00 target price on shares of Jazz Pharmaceuticals PLC and gave the stock a “buy” rating in a research report on Thursday, April 27th. One research analyst has rated the stock with a sell rating, two have given a hold rating and nineteen have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $182.96.
In other Jazz Pharmaceuticals PLC news, Director Rick E. Winningham sold 5,000 shares of the firm’s stock in a transaction dated Thursday, June 1st. The stock was sold at an average price of $150.00, for a total value of $750,000.00. Following the transaction, the director now directly owns 10,391 shares of the company’s stock, valued at $1,558,650. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael Patrick Miller sold 200 shares of the firm’s stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $150.65, for a total value of $30,130.00. Following the completion of the transaction, the executive vice president now directly owns 22,223 shares in the company, valued at $3,347,894.95. The disclosure for this sale can be found here. Insiders sold a total of 10,600 shares of company stock valued at $1,641,720 over the last quarter. 4.30% of the stock is owned by corporate insiders.
About Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).
Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.
